Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

January 16, 2020

Primary Completion Date

February 11, 2021

Study Completion Date

March 10, 2021

Conditions
Parkinson Disease
Interventions
DRUG

AKST4290

Oral AKST4290

DRUG

Placebo

Oral Placebo

Trial Locations (22)

30331

Atlanta Center for Medical Research, Atlanta

48322

Henry Ford Hospital West Bloomfield, West Bloomfield

74136

Movement Disorder Clinic of Oklahoma PLLC, Tulsa

Unknown

AS Ida-Tallinna Keskhaigla / East Tallinn Central Hospital, Tallinn

Astra Kliinik / Astra Team Clinic, Tallinn

Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden

Krankenhaus Agatharied GmbH, Hausham

Paracelsus-Elena-Klinik Kassel, Kassel

Universitatsklinikum Leipzig, Leipzig

UKGM Marburg, Marburg

Klinikum rechts der Isar der Technischen Universität München, München

Universitätsklinikum Tübingen, Tübingen

Universitätsklinikum Ulm, Ulm

Centrum Medyczne PRATIA/ Medical Center PRATIA, Częstochowa

Krakowska Akademia Neurologii/ Cracow Academy of Neurology, Krakow

Instytut Zdrowia Dr Boczarska-Jedynak Spolka Z Oraganiczona Odpowiedzialnoscia Spolka Komandytowa/ Institute of Health dr Boczarska-Jedynak, Oświęcim

Medicome SP. ZO. O./ Medicome, Oświęcim

Neurologiczny Nzoz Centrum Leczenia Sm Osrodek Badan Klinicznych, Plewiska

Euro-Neuro, s.r.o., Neurologická ambulancia, Bratislava

Nemocnica Kramáre II. Neurologická klinika LF UK a UNB /2nd Dept. Of Neurology, Comenius University Faculty of Medicine and University Hospital Bratislava, Bratislava

Nemocnica s poliklinikou Sv. Lukáša Galanta, a. s Neurologické oddelenie /Neurology Dpt., NsP Galanta, Galanta

Univerzitná nemocnica Martin Neurologická klinika/University hospital Martin, Clinic of Neurology, Martin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alkahest, Inc.

INDUSTRY